ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2010
Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Cortactin Facilitates Malignant Transformation of Dysplastic Cells in Gastric Cancer Development.Cellular and molecular gastroenterology and hepatology · 2025Article
- Requirement of Site-Specific Tyrosine Phosphorylation of Cortactin in Retinal Neovascularization and Vascular Leakage.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Effects of Cortactin Expression on Prognosis in Patients with Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Prognostic impact of cortactin in patients with hypopharyngeal cancer and its role for tegafur-uracil maintenance after adjuvant chemoradiotherapy.American journal of cancer research · 2023Article
- MiRNA-545 negatively regulates the oncogenic activity of EMS1 in gastric cancer.Cancer medicine · 2018Article
- Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway.Oncotarget · 2017Article
- WIP and WICH/WIRE co-ordinately control invadopodium formation and maturation in human breast cancer cell invasion.Scientific reports · 2016Article
- Article
- Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.International journal of experimental pathology · 2015Article
- Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo.BMC complementary and alternative medicine · 2015Article
- Regulators of Actin Dynamics in Gastrointestinal Tract Tumors.Gastroenterology research and practice · 2015Review
- Movers and shakers: cell cytoskeleton in cancer metastasis.British journal of pharmacology · 2014Review
- Endocytosis and cancer.Cold Spring Harbor perspectives in biology · 2013Review
- Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma.Frontiers in immunology · 2013Article
- Expression of cortactin and focal adhesion kinase in colorectal adenocarcinoma: correlation with clinicopathologic parameters and their prognostic implication.Korean journal of pathology · 2012Article
- An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.Human molecular genetics · 2012Article
- Cortactin in cell migration and cancer at a glance.Journal of cell science · 2012Review
- Nucleating actin for invasion.Nature reviews. Cancer · 2011Review
- The Pathogenic Effect of Cortactin Tyrosine Phosphorylation in Cutaneous Squamous Cell Carcinoma.In vivo (Athens, Greece)Article
- Cortactin: a multifunctional regulator of cellular invasiveness.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II-III colorectal cancer (CRC).
methodsTwo hundred and five stages II-III CRC patients were included in this study. Formalin-fixed paraffin-embedded specimens were stained for cortactin and the correlation between the staining, its clinicopathological parameters, and its prognostic power were analyzed statistically.
resultsOf the 205 patients studied, 113 cases (55.1%) were strongly positive for cortactin. Cortactin expression correlated with tumor invasion (P = 0.018), histological grade (P = 0.004), and preoperative CEA level (P < 0.001). In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively). In multivariate analysis, tumor invasion, preoperative CEA level, and cortactin expression maintained their independent prognostic influence on disease-free survival (P = <0.001, 0.003, and 0.008, respectively). However, tumor invasion, AJCC stage, and cortactin expression influenced overall survival (P = 0.036, <0.001, and 0.004, respectively).
conclusionsCortactin may be a good biomarker to be applied in the clinical setting to predict the prognosis of patients with completely resected pathologic stages II-III CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.